Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat.com A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHReported by Nathan Reiff. Originally Published: 2/12/2026. 
In Brief - AstraZeneca, Edwards Lifesciences, and Zimmer Biomet all reported earnings on the same day, but with vastly different results.
- Of these, AstraZeneca's impressive oncology medicine sales growth stands out, having driven significant top-line growth.
- Edwards and Zimmer both saw notable successes in the latest quarter, but also face sizable challenges.
More than just a financial check-up, earnings for companies in the healthcare sector offer investors a key window into a firm's pipeline and development progress. Even well-established, stable firms can surprise with growth when they release a new blockbuster drug or device, and earnings season lets management provide insight beyond what typical regulatory announcements—like FDA approvals—convey. When healthcare companies report on the same day, investors face a busy stretch of news and trading decisions. On Feb. 10, 2026, three major names in the sector—AstraZeneca (NASDAQ: AZN), Edwards Lifesciences (NYSE: EW), and Zimmer Biomet (NYSE: ZBH)—each released full-year and Q4 2025 results. Below are the highlights and takeaways for healthcare investors planning next steps. AstraZeneca Firms Up Cancer Business in a Strong Overall Quarterly Performance Watch Now! Porter Stansberry & Luke Lango join forces to unveil:
The Three Titanic Forces Converging To Unleash A New 1776 Moment
"We have never seen wealth created at this size and speed" MIT Researcher Click here for the stocks to buy and sell now U.K.-based pharma giant AstraZeneca closed out 2025 by reinforcing its position as a leader in oncology: cancer medicines accounted for roughly 44% of product sales in the quarter. Sales of key oncology drugs such as Imfinzi and Enhertu rose as much as 48% year over year, helping drive total revenue up 8.6% to $58.7 billion for the year. After-tax profit jumped alongside revenue, climbing to $10.2 billion from $7 billion in the prior-year quarter. The board declared a second interim dividend that is 7 cents higher than last year's payout. Investors also have several clinical catalysts to watch: management said about 20 Phase 3 readouts are expected in 2026. The company reiterated expectations for solid increases in both total revenue and core earnings per share (EPS) for the full year 2026. Following its strong results, AZN shares climbed nearly 3% in after-hours trading. Although 10 of 11 analysts rate AZN a Buy or equivalent, Wall Street remains mindful of valuation—the consensus price target of $95.75 implies potential downside of nearly 51% from current levels. TAVR Momentum Fuels Edwards Sales Growth, Though Investors Should Be Mindful of Earnings and Margin Limitations Edwards manufactures replacement heart valves, related surgical devices, and monitoring systems. Its Q4 2025 results were largely positive, with sales rising 13.3% year over year driven by strong transcatheter aortic valve replacement (TAVR) momentum and uptake of the latest SAPIEN valve iteration. That said, adjusted EPS missed analyst expectations, and gross profit margin declined by 0.8 percentage points year over year. Despite the mixed signals, Edwards reiterated its 2026 outlook calling for sales growth of 8%–10% and EPS between $2.90 and $3.05. EW shares jumped above $80 in after-hours trading, about 4% higher than the close. Roughly two-thirds of analysts covering EW rate the stock a Buy, and the consensus price target of $96.77 implies roughly 25% upside. Orthopedic Demand Remains High, But Zimmer Faces Some Headwinds Going Forward Zimmer Biomet, a maker of joint-replacement systems and orthopedic implants, saw its shares rise more than 3% after reporting EPS of $2.42—4 cents above consensus—and revenue of $2.2 billion, up nearly 11% year over year and slightly ahead of estimates. Strong demand for its orthopedic products supported both top- and bottom-line growth. The company is also shifting focus more toward the U.S., which accounts for nearly 60% of sales. With insured patients driving higher utilization, near-term demand for Zimmer's products is expected to remain robust. However, Zimmer warned that tariffs and related cost pressures could weigh on 2026 results, leading management to issue conservative guidance: adjusted EPS of $8.30–$8.45 and free cash flow improvement of 8%–10%, according to the latest report. Analysts remain divided on ZBH, assigning the company an overall Hold rating, though the consensus projects about 15% upside from current levels (source).
| 
